Royalty Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Royalty Pharma Plc
RPRX Stock  USD 33.41  0.39  1.18%   
Royalty Pharma financial statements provide useful quarterly and yearly information to potential Royalty Pharma Plc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Royalty Pharma financial statements helps investors assess Royalty Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Royalty Pharma's valuation are summarized below:
Gross Profit
1.5 B
Profit Margin
0.3795
Market Capitalization
19 B
Enterprise Value Revenue
8.8998
Revenue
2.3 B
We have found one hundred twenty available trending fundamental ratios for Royalty Pharma Plc, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Royalty Pharma Plc recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Enterprise Value is likely to drop to about 17 B in 2025

Royalty Pharma Total Revenue

2.38 Billion

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Royalty Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets19.1 B18.2 B9 B
Slightly volatile
Other Current Liabilities254.6 M242.5 M117 M
Slightly volatile
Total Current Liabilities1.3 B1.3 B368.3 M
Slightly volatile
Total Stockholder Equity10.9 B10.3 B4 B
Slightly volatile
Other Liabilities2.4 M2.2 M2.6 M
Slightly volatile
Accounts Payable14 M13.4 M6.4 M
Slightly volatile
Cash975.5 M929 M684.9 M
Slightly volatile
Other Assets16.3 B15.5 B9.7 B
Slightly volatile
Common Stock Shares Outstanding418.8 M592.7 M399.8 M
Slightly volatile
Short Term Investments55.3 M58.2 M457.7 M
Very volatile
Inventory1.091.1592 M
Pretty Stable
Other Current Assets855.7 M814.9 M112 M
Slightly volatile
Total Liabilities8.3 B7.9 B3.9 B
Slightly volatile
Common Stock49.2 K51.8 K615.5 M
Very volatile
Property Plant Equipment2.6 K2.7 K48 K
Slightly volatile
Intangible Assets1.9 M2 M30.7 M
Pretty Stable
Net Tangible Assets3.7 B6.5 B2.9 B
Slightly volatile
Total Current Assets1.6 B1.8 B1.2 B
Slightly volatile
Short and Long Term Debt Total8.4 B7.6 B7.1 B
Slightly volatile
Net Debt6.1 B6.7 B5.1 B
Slightly volatile
Non Current Assets Total14.8 B16.4 B11.2 B
Slightly volatile
Non Currrent Assets Other17 B16.2 B3 B
Slightly volatile
Long Term Debt6.9 B6.6 B6.3 B
Slightly volatile
Cash And Short Term Investments1.4 B987.2 M2 B
Slightly volatile
Net Receivables25.6 M27 M218.1 M
Pretty Stable
Common Stock Total Equity91.5 K96.3 K2.1 B
Slightly volatile
Long Term Debt Total6.9 B7 B6.3 B
Slightly volatile
Liabilities And Stockholders Equity17.9 B18.2 B13.9 B
Slightly volatile
Non Current Liabilities Total6.9 B6.6 B6.3 B
Slightly volatile
Net Invested Capital13.6 B14.6 B11.8 B
Slightly volatile
Long Term Investments14.6 B16.4 B11.1 B
Slightly volatile
Short and Long Term Debt703.6 M1.1 B541 M
Slightly volatile
Capital Stock92.3 K97.2 K2.1 B
Slightly volatile
Net Working Capital521.1 M548.5 M1.7 B
Slightly volatile
Short Term Debt1.8 B1.1 B932.2 M
Slightly volatile
Current Deferred Revenue24.8 M27.9 M30.5 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity3.6 B3.5 B4.7 B
Slightly volatile
Retained Earnings Total Equity2.3 B2.3 B2 B
Slightly volatile
Capital Surpluse3.7 B4.2 B3.1 B
Slightly volatile
Non Current Liabilities Other12.7 M12.1 M3.6 M
Slightly volatile

Royalty Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Research Development1.9 M2 M72.9 M
Pretty Stable
Selling General Administrative248.8 M237 M109.4 M
Slightly volatile
Interest Income45.8 M47.3 M26.7 M
Slightly volatile
Depreciation And Amortization477.1 M454.4 M105.7 M
Slightly volatile
Other Operating Expenses884.4 M972 M745.3 M
Slightly volatile
EBITDA1.2 B1.3 B1.4 B
Slightly volatile
Non Recurring1.2 B1.4 B1.5 B
Slightly volatile

Royalty Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow971.6 M929 M1.4 B
Slightly volatile
Begin Period Cash Flow453.2 M477 M1.4 B
Slightly volatile
Other Non Cash Items1.8 B1.4 B1.6 B
Pretty Stable
Dividends Paid403.9 M376.5 M599.3 M
Slightly volatile
Stock Based Compensation2.4 M2.3 M4.5 M
Slightly volatile
Cash And Cash Equivalents Changes145.1 M152.7 M597.3 M
Slightly volatile
Cash Flows Other Operating2.2 B2.4 B2 B
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.795.043711.1924
Slightly volatile
Dividend Yield0.03620.0330.0391
Slightly volatile
PTB Ratio1.051.10413.8975
Slightly volatile
Days Sales Outstanding4.134.3458111
Slightly volatile
Book Value Per Share15.1423.104815.1964
Slightly volatile
Free Cash Flow Yield0.250.24250.1256
Slightly volatile
Operating Cash Flow Per Share4.126.18594.5826
Slightly volatile
Stock Based Compensation To Revenue0.00150.0010.0021
Slightly volatile
PB Ratio1.051.10413.8975
Slightly volatile
EV To Sales13.17.995814.177
Slightly volatile
Free Cash Flow Per Share4.126.18594.5826
Slightly volatile
ROIC0.07060.04640.0624
Very volatile
Inventory Turnover0.150.13414.0447
Slightly volatile
Net Income Per Share2.491.9191.87
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-4369
Pretty Stable
Payables Turnover31.4542.5230.5276
Very volatile
Sales General And Administrative To Revenue0.06360.10470.0729
Slightly volatile
Average Inventory0.550.57246.4 M
Slightly volatile
Research And Ddevelopement To Revenue8.0E-49.0E-40.0592
Pretty Stable
Cash Per Share4.322.20553.6133
Pretty Stable
POCF Ratio3.924.12399.1349
Slightly volatile
Interest Coverage5.025.71685.3363
Slightly volatile
Payout Ratio0.420.43831.0076
Pretty Stable
PFCF Ratio3.924.12399.1349
Slightly volatile
Days Payables Outstanding8.448.8948.8846
Slightly volatile
Income Quality1.882.08071.7531
Slightly volatile
ROE0.07890.08310.1445
Pretty Stable
EV To Operating Cash Flow11.916.537612.6923
Slightly volatile
PE Ratio12.6313.293454.4665
Pretty Stable
Return On Tangible Assets0.08710.04710.1019
Slightly volatile
EV To Free Cash Flow11.916.537612.6923
Slightly volatile
Earnings Yield0.04590.07520.0455
Slightly volatile
Intangibles To Total Assets1.0E-41.0E-40.2426
Slightly volatile
Net Debt To EBITDA4.485.17294.3686
Slightly volatile
Current Ratio1.371.43767.5834
Slightly volatile
Receivables Turnover88.1983.988713.324
Slightly volatile
Graham Number20.1231.58521.004
Slightly volatile
Shareholders Equity Per Share11.8223.104812.384
Slightly volatile
Debt To Equity1.250.7361.1884
Slightly volatile
Revenue Per Share3.765.05784.0201
Slightly volatile
Interest Debt Per Share12.7217.51113.9284
Slightly volatile
Debt To Assets0.520.41770.4983
Slightly volatile
Enterprise Value Over EBITDA20.6414.011124.3473
Slightly volatile
Short Term Coverage Ratios4.763.194.3266
Slightly volatile
Price Earnings Ratio12.6313.293454.4665
Pretty Stable
Operating Cycle4.134.3458310
Very volatile
Price Book Value Ratio1.051.10413.8975
Slightly volatile
Days Of Payables Outstanding8.448.8948.8846
Slightly volatile
Dividend Payout Ratio0.420.43831.0076
Pretty Stable
Price To Operating Cash Flows Ratio3.924.12399.1349
Slightly volatile
Price To Free Cash Flows Ratio3.924.12399.1349
Slightly volatile
Pretax Profit Margin0.740.58790.6063
Pretty Stable
Ebt Per Ebit1.081.03020.9803
Very volatile
Operating Profit Margin0.540.57070.6013
Pretty Stable
Effective Tax Rate0.340.320.3505
Slightly volatile
Company Equity Multiplier2.661.76192.4024
Pretty Stable
Long Term Debt To Capitalization0.560.39010.527
Slightly volatile
Total Debt To Capitalization0.570.4240.5374
Slightly volatile
Return On Capital Employed0.110.07610.0908
Pretty Stable
Debt Equity Ratio1.250.7361.1884
Slightly volatile
Ebit Per Revenue0.540.57070.6013
Pretty Stable
Quick Ratio1.371.43767.448
Slightly volatile
Dividend Paid And Capex Coverage Ratio4.057.35523.6275
Slightly volatile
Net Income Per E B T0.70.64540.6862
Slightly volatile
Cash Ratio0.70.74114.0239
Slightly volatile
Operating Cash Flow Sales Ratio0.81.22310.9382
Slightly volatile
Days Of Inventory Outstanding1.0E-41.0E-4369
Pretty Stable
Days Of Sales Outstanding4.134.3458111
Slightly volatile
Cash Flow Coverage Ratios0.250.36370.2637
Slightly volatile
Price To Book Ratio1.051.10413.8975
Slightly volatile
Price Cash Flow Ratio3.924.12399.1349
Slightly volatile
Enterprise Value Multiple20.6414.011124.3473
Slightly volatile
Debt Ratio0.520.41770.4983
Slightly volatile
Cash Flow To Debt Ratio0.250.36370.2637
Slightly volatile
Price Sales Ratio4.795.043711.1924
Slightly volatile
Return On Assets0.07630.04710.0649
Very volatile
Asset Turnover0.150.12420.1451
Slightly volatile
Net Profit Margin0.530.37940.4428
Very volatile
Gross Profit Margin0.690.76190.8927
Slightly volatile
Price Fair Value1.051.10413.8975
Slightly volatile
Return On Equity0.07890.08310.1445
Pretty Stable

Royalty Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12.7 B14.7 B15.7 B
Slightly volatile
Enterprise Value17 B20 B21.1 B
Pretty Stable

Royalty Fundamental Market Drivers

Forward Price Earnings10.627
Cash And Short Term Investments987.2 M

Royalty Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue27.9 M24.8 M
Total Revenue2.3 B2.4 B
Cost Of Revenue644.8 M677 M
Sales General And Administrative To Revenue 0.10  0.06 
Revenue Per Share 5.06  3.76 
Ebit Per Revenue 0.57  0.54 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY